Skip to main content

Table 7 Lys751Gln/Asp312Asn genotypes in the study and control groups

From: Some Molecular and Clinical Aspects of Genetic Predisposition to Malignant Melanoma and Tumours of Various Site of Origin

Lys751Gln

Asp312Asn

Melanoma

Newborns

OR (95% CI), p

Breast cancer

OR (95% CI), p

  

(n = 423)

(n = 1017)

 

(n = 1713)

 

AA

GG

115

267

1.0 (n.s.)

494

1.1 (n.s.)

  

(27.2%)

(26.3%)

 

(28.8%)

 

AA

AG

28

104

0.6 (n.s.)

153

0.9 (n.s.)

  

(6.6%)

(10.2%)

 

(8.9%)

 

AA

AA

2

16

0.3 (n.s.)

17

0.6 (n.s.)

  

(0.5%)

(1.6%)

 

(1%)

 

AC

GG

46

107

1.0 (n.s.)

151

0.8 (n.s.)

  

(10.9%)

(10.5%)

 

(8.8%)

 

AC

AG

131

334

1.0 (n.s.)

559

1.0 (n.s.)

  

(31%)

(32.8%)

 

(32.6%)

 

AC

AA

28

49

1.4 (n.s.)

77

1.0 (n.s.)

  

(6.6%)

(4.8%)

 

(4.5%)

 

CC

GG

7

20

0.8 (n.s.)

22

0.7 (n.s.)

  

(1.6%)

(2%)

 

(1.3%)

 

CC

AG

27

51

1.3 (n.s.)

67

0.8 (n.s.)

  

(6.4%)

(5%)

 

(3.9%)

 

CC

AA

39

69

1.4 (n.s.)

173

1.5 (1.2–2.1)

  

(9.2%)

(6.8%)

 

(10.1%)

0.004 (0.016)1

  1. 1p value calculated with the χ2 test (Bonferroni adjusted value in parantheses)
Back to article page

Hereditary Cancer in Clinical Practice

ISSN: 1897-4287